Skip to content

Study · Randomized controlled trial · 2018

6 results

Pharmacokinetics and Safety of Intravenous Murepavadin Infusion in Healthy Adult Subjects Administered Single and Multiple Ascending Doses.

Wach A, Dembowsky K, Dale GE

Antimicrobial agents and chemotherapy27 Mar 2018Cited by 34 (Europe PMC)

PMID29437621 (opens in a new tab)PMCIDPMC5913942 (opens in a new tab)DOI10.1128/aac.02355-17 (opens in a new tab)PepBankPUB-29437621
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In healthy men, single-dose murepavadin geometric mean half-life ranged from 2.52 to 5.30 h and was consistent across doses.

    In plain wordsIn healthy men, murepavadin half-life ranged from 2.52 to 5.30 h after a single dose.

    Peptide
    Murepavadin
    Outcome
    Not applicableSingle-dose half-life
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenous infusionAs given in this study (human).

    Measurements

    Geometric mean half-life
    2.52 to 5.3 h
    Not specified

    Source sentences

    Summary
    After a single dose of murepavadin, the geometric mean half-life (2.52 to 5.30 h), the total clearance (80.1 to 114 ml/h/kg), and the volume of distribution (415 to 724 ml/kg) were consistent across dose levels.
    2 context sentences
    Summary · context
    The pharmacokinetics (PK) and safety of single and multiple doses of murepavadin were investigated in healthy male subjects.
    Summary · context
    Part A of the study was a double-blind, randomized, placebo-controlled, single-ascending-dose investigation in 10 sequential cohorts where each cohort comprised 6 healthy male subjects; 4 subjects were randomized to murepavadin, and 2 subjects were randomized to placebo.
  2. 02HumanRandomized controlled trialPharmacokinetics

    In healthy men, single-dose murepavadin total clearance ranged from 80.1 to 114 ml/h/kg and was consistent across doses.

    In plain wordsIn healthy men, murepavadin clearance ranged from 80.1 to 114 ml/h/kg after a single dose.

    Peptide
    Murepavadin
    Outcome
    Not applicableSingle-dose total clearance
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenous infusionAs given in this study (human).

    Measurements

    Total clearance
    80.1 to 114 ml/h/kg
    Not specified

    Source sentences

    Summary
    After a single dose of murepavadin, the geometric mean half-life (2.52 to 5.30 h), the total clearance (80.1 to 114 ml/h/kg), and the volume of distribution (415 to 724 ml/kg) were consistent across dose levels.
    2 context sentences
    Summary · context
    The pharmacokinetics (PK) and safety of single and multiple doses of murepavadin were investigated in healthy male subjects.
    Summary · context
    Part A of the study was a double-blind, randomized, placebo-controlled, single-ascending-dose investigation in 10 sequential cohorts where each cohort comprised 6 healthy male subjects; 4 subjects were randomized to murepavadin, and 2 subjects were randomized to placebo.
  3. 03HumanRandomized controlled trialPharmacokinetics

    In healthy men, single-dose murepavadin distribution volume ranged from 415 to 724 ml/kg and was consistent across doses.

    In plain wordsIn healthy men, murepavadin distribution volume ranged from 415 to 724 ml/kg after a single dose.

    Peptide
    Murepavadin
    Outcome
    Not applicableSingle-dose distribution volume
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenous infusionAs given in this study (human).

    Measurements

    Volume of distribution
    415 to 724 ml/kg
    Not specified

    Source sentences

    Summary
    After a single dose of murepavadin, the geometric mean half-life (2.52 to 5.30 h), the total clearance (80.1 to 114 ml/h/kg), and the volume of distribution (415 to 724 ml/kg) were consistent across dose levels.
    2 context sentences
    Summary · context
    The pharmacokinetics (PK) and safety of single and multiple doses of murepavadin were investigated in healthy male subjects.
    Summary · context
    Part A of the study was a double-blind, randomized, placebo-controlled, single-ascending-dose investigation in 10 sequential cohorts where each cohort comprised 6 healthy male subjects; 4 subjects were randomized to murepavadin, and 2 subjects were randomized to placebo.
  4. 04HumanRandomized controlled trialPharmacokinetics

    In healthy men, murepavadin pharmacokinetics were dose proportional and linear across evaluated dosing regimens.

    In plain wordsIn healthy men, murepavadin pharmacokinetics were linear and proportional to dose.

    Peptide
    Murepavadin
    Outcome
    Not applicableDose proportionality and linearity
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenous infusionAs given in this study (human).

    Source sentences

    Summary
    The pharmacokinetics of the dosing regimens evaluated were dose proportional and linear.
    2 context sentences
    Summary · context
    The pharmacokinetics (PK) and safety of single and multiple doses of murepavadin were investigated in healthy male subjects.
    Summary · context
    Part B was a double-blind, randomized, placebo-controlled, multiple-ascending-dose investigation in 3 sequential cohorts.
  5. 05HumanRandomized controlled trialSafety outcome

    In healthy men, murepavadin was well tolerated, with transient and generally mild adverse events.

    In plain wordsIn healthy men, murepavadin adverse events were temporary and generally mild.

    Peptide
    Murepavadin
    Outcome
    Direction not reportedTolerability and adverse events
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · intravenous infusionAs given in this study (human).

    Source sentences

    Summary
    Murepavadin was well tolerated, adverse events were transient and generally mild, and no dose-limiting toxicity was identified.
    2 context sentences
    Summary · context
    The pharmacokinetics (PK) and safety of single and multiple doses of murepavadin were investigated in healthy male subjects.
    Summary · context
    Part B was a double-blind, randomized, placebo-controlled, multiple-ascending-dose investigation in 3 sequential cohorts.
  6. 06HumanRandomized controlled trialSafety outcome

    In healthy men, no dose-limiting toxicity was identified with murepavadin.

    In plain wordsIn healthy men, researchers identified no dose-limiting toxicity with murepavadin.

    Peptide
    Murepavadin
    Outcome
    Direction not reportedDose-limiting toxicity
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · intravenous infusionAs given in this study (human).

    Source sentences

    Summary
    Murepavadin was well tolerated, adverse events were transient and generally mild, and no dose-limiting toxicity was identified.
    2 context sentences
    Summary · context
    The pharmacokinetics (PK) and safety of single and multiple doses of murepavadin were investigated in healthy male subjects.
    Summary · context
    Part B was a double-blind, randomized, placebo-controlled, multiple-ascending-dose investigation in 3 sequential cohorts.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.